Seller record · Telehealth service

Taurus

Fails 2 of 8 criteria. S4, compounding disclosure: The home page lists FDA-approved medications among its promises above the peptide program, while the NAD+ and sermorelin pages say the therapies are not FDA-approved and do not say the peptides are compounded. 1 more criterion also fails; see the table below.

At a glance

TaurusTelehealth service

6/8criteria passed
Price
NAD+, sermorelin and glutathione $79 the first month against a listed $179
Sells
NAD+ injection, sermorelin, glutathione, and 3 more
FDA letters
None on file
Visit TaurusSee all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A men's health telehealth service selling NAD+, sermorelin and glutathione injections alongside testosterone therapy and a liquid erectile dysfunction treatment, through a contracted clinician network. Its terms name four partner pharmacies, and its home page calls its medications FDA-approved while the peptide pages say those therapies are not.

Operating entity Taurus Medical, Inc.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSTaurus' website; Taurus' NAD+ page; Taurus' terms
S2Prescription gatingPASSTaurus' NAD+ page; Taurus' refunds page
S3Pharmacy identificationPASSTaurus' terms
S4Compounding disclosureFAILTaurus' website; Taurus' NAD+ page; Taurus' sermorelin page
S5Analytical documentationFAILTaurus' peptides page; Taurus' terms
S6Business addressPASSTaurus' terms
S7Price disclosurePASSTaurus' peptides page; Taurus' NAD+ page; Taurus' sermorelin page; Taurus' terms
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSLicensed clinicians approve and prescribe medications as appropriate, and the product pages say prescriptions are at the discretion of the medical providers. The terms name OpenLoop Health, Inc. as the partner medical services organization.Source: Taurus' website; Taurus' NAD+ page; Taurus' terms.
S2PASSThe buy button on each peptide page leads to the seller's own intake, and the refund policy says the first month is charged when the intake form is completed and refunded in full if the provider disqualifies the buyer.Source: Taurus' NAD+ page; Taurus' refunds page.
S3PASSThe terms name four partner pharmacies with street addresses: RedRock Pharmacy in St. George, UT, Health Warehouse in Florence, KY, Precision Compounding Pharmacy in Bellmore, NY and Triad Rx in Daphne, AL.Source: Taurus' terms.
S4FAILThe home page lists FDA-approved medications among its promises above the peptide program, while the NAD+ and sermorelin pages say the therapies are not FDA-approved and do not say the peptides are compounded.Source: Taurus' website; Taurus' NAD+ page; Taurus' sermorelin page.
S5FAILNo certificate of analysis or lot document is published on the peptide pages, the terms or the refund policy.Source: Taurus' peptides page; Taurus' terms.
S6PASSTaurus Medical, Inc. at 2810 North Church Street, PMB 371469, Wilmington, DE 19802, a private mailbox, printed in the terms and in their contact block. The terms name California law.Source: Taurus' terms.
S7PASSNAD+, sermorelin and glutathione injections each at $79 for the first month against a struck-through $179 a month, with a banner calling the first-month price a limited-time offer. The terms add a recurring membership fee of $17.99 per billing period.Source: Taurus' peptides page; Taurus' NAD+ page; Taurus' sermorelin page; Taurus' terms.
S8PASSNo FDA warning letter names Taurus or Taurus Medical, Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: NAD+ injection, sermorelin, glutathione, testosterone replacement therapy, enclomiphene, Charge liquid ED treatment.

Visit Taurus

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.